VALGANCICLOVIR TEVA 450mg tablets medication leaflet

J05AB14 valganciclovir • Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Valganciclovir is an antiviral medication used for the treatment and prevention of cytomegalovirus (CMV) infections in immunocompromised patients, such as those who have undergone organ transplantation or are infected with HIV. It is a prodrug of ganciclovir, which is active against CMV by inhibiting viral DNA synthesis, thereby preventing viral replication.

The medication is administered orally, usually once or twice daily, depending on the therapeutic indication and the patient's condition. The dosage is adjusted based on the patient's renal function to reduce the risk of toxicity.

Common side effects include nausea, diarrhea, anemia, neutropenia, and fatigue. In rare cases, severe adverse reactions such as renal failure, severe myelosuppression, or allergic reactions may occur.

Valganciclovir is an essential medication for managing CMV infections in immunocompromised patients, helping to prevent severe complications associated with this viral infection.

General data about VALGANCICLOVIR TEVA 450mg

Substance: valganciclovir

Date of last drug list: 01-07-2020

Commercial code: W60756001

Concentration: 450mg

Pharmaceutical form: tablets

Quantity: 60

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for valganciclovir

Concentrations available for valganciclovir

450mg, 50mg/ml